-
The Institute of Zoology Collaborated to Discover the Mechanism of PCBP2 Regulation of cGAS-DNA Phase Transition
Time of Update: 2022-04-26
In terms of the regulatory mechanism, the researchers found that PCBP2 can significantly inhibit the phase separation and enzymatic activity of cGAS-DNA in vitro .
-
The new crown DNA vaccine will start phase 3 clinical Ai Di Weixin has exclusive rights in Greater China
Time of Update: 2021-05-09
INO-4800 is a candidate DNA vaccine developed by INOVIO, which can be used against the coronavirus SARS-CoV-2 that causes new coronary pneumonia.
In January 2020, Ai Di Weixin and INOVIO reached a cooperation to develop INO-4800 in China.
-
The first DNA HPV vaccine officially launched Phase III clinical trials in China
Time of Update: 2021-04-24
On March 26th, according to a report from Oriental Gaosheng, its subsidiary company Oriental Strategy’s VGX-3100 project has been approved by the Office of Genetics, officially launching the combination of VGX-3100 and the device CELLECTRATM 5PSP in the country for the treatment of HPV-16/18-related high cervical squamous Phase III clinical study of intraepithelial lesions (HSIL).
-
Inovio announces the first phase III clinical success of innovative DNA immunotherapy treatment for cervical cancer
Time of Update: 2021-03-19
Inovio announced the positive results of the first phase III clinical trial of VGX-3100 for cervical precancerous lesions.
INOVIO announced in early January this year: For the precancerous lesions of the vulva caused by HPV infection, the Phase II clinical trial showed good clinical effectiveness, safety and tolerability.
-
Dynamic Analysis of Viral Populations by Direct DNA Sequencing and Solid-Phase Technology
Time of Update: 2021-02-12
Among the most important developments towards automated systems has been the introduction of the polymerase chain reaction ( PCR ) and the replacement of isotopic labels by fluorescent dyes and on-line monitoring of the DNA sequence.
-
Lancet Sub-Journal: Phase I clinical phase I of the COVID-19 DNA candidate vaccine INO-4800, triggering immunogenicity in all patients
Time of Update: 2021-01-02
the INO-4800 has good safety and tolerance and no serious adverse events are reported.
clinical data found that the INO-4800 had good safety and tolerance and did not report serious adverse events.
-
Synthesis of DNA-Binding Polyamides: Robust Solid-Phase Methods for Coupling Heterocyclic Aromatic Amino Acids
Time of Update: 2020-12-16
Currently, most DNA-binding therapeutics target short sequences of DNA with rather low selectivity, causing deleterious effects in both diseased and healthy cells ( 1 ).
Thus, the development of molecules that target longer, more cell-type-specific sequences of DNA is of great interest.
-
Entos Pharmaceuticals has received funding for phase I clinical trials of the COVID-19 DNA vaccine.
Time of Update: 2020-10-30
We are pleased to use this funding to advance Covigenix's Phase I human clinical trials." urgent need to develop and produce safe and effective vaccines against COVID-19 for Canadians and the global population to ensure lasting protection.
-
Baiyunshan announced the results of phase Ⅱ B clinical trial of therapeutic double plasmid HBV DNA vaccine project
Time of Update: 2020-04-03
On December 14, 2013, it was announced that the therapeutic double plasmid HBV DNA vaccine project invested by Guangzhou Baiyunshan Pharmaceutical Co., Ltd with a 60% interest and developed by the 458